Novartis Patient Assistance Foundation

The Novartis Patient Assistance Foundation (NPAF) operates as a pharmaceutical patient assistance program — an IRS 501(c)(3) operating foundation (NTEE code E60) that functions as a medication access conduit rather than a traditional discretionary grant-maker. Every dollar of NPAF's $2.87B in FY2023 program expenditure went to 'Various Individuals' as medication donations, with zero grants to organizations. Understanding this architecture is the essential first step: no RFP, no letter of inquiry, no competitive proposal.

Three types of stakeholders engage with NPAF productively. Individual patients apply directly when they are uninsured or underinsured, US residents, and meet income guidelines for their specific Novartis medication. Prescribing healthcare providers serve as mandatory co-signatories on every application — their participation is not optional but structural. Healthcare organizations — community health centers, nonprofit clinics, hospital social work departments, patient advocacy nonprofits, and insurance navigators — function as high-value intermediaries who identify eligible patients, coordinate the dual patient-prescriber application workflow, and track renewals to prevent coverage gaps.

For healthcare organizations, NPAF's value proposition is its operational accessibility: rolling enrollment year-round with no submission deadlines, no competitive review, and binary eligibility criteria. An organization that builds a standardized NPAF screening protocol into its intake process can systematically connect eligible patients to $22,600+ in average annual medication value (based on 127,000 patients served at $2.87B distributed in 2023).

The foundation's giving philosophy is shaped by Novartis's commercial interests and social mission simultaneously: NPAF only covers Novartis medications, and coverage tracks Novartis's live drug portfolio. As Novartis expands into rare disease and oncology with higher-cost agents, NPAF's average assistance value per patient grows. This makes the NPAF portfolio especially valuable for organizations serving cancer patients, heart failure patients on Entresto, or autoimmune patients on Cosentyx.

Leadership (President Tom Kendris, CFO Katherine Vazquez, Treasurer John McKenna, and a nine-member board) serves entirely without compensation — reinforcing that NPAF is structured for maximum medication throughput, not administrative overhead.

NPAF's 'grants' are entirely medication-based: Novartis donates drugs at wholesale or retail value through the foundation to qualifying individuals, with all expenditure recorded as grants paid. This makes NPAF one of the largest pharmaceutical patient assistance programs in the US by dollar volume — yet it serves only one grantee category (individuals receiving Novartis medications) and one program purpose (medication access).

Annual program scale: - FY2024: $3.38B total revenue (990 filed Oct 2025; grants paid not yet reported) - FY2023: $2.87B grants paid, $2.94B total giving, $2.83B contributions received - FY2022: $2.87B grants paid, $2.94B total giving, $3.08B revenue - FY2021: $2.55B grants paid, $2.60B total giving - FY2020: $3.26B grants paid (pandemic-period peak) - FY2019: $1.82B grants paid - FY2015: $542M grants paid - FY2014: $457M grants paid

The growth trajectory — a 6.3x increase from $457M (2014) to $2.87B (2023) — reflects Novartis's pipeline shift toward high-cost specialty biologics. As drugs like Zolgensma ($2.1M/dose), Kymriah, Kisqali, and Leqvio have launched, NPAF's average per-patient assistance value has climbed substantially. With ~127,000 patients served annually, the implied average medication value per patient is approximately $22,600/year in 2023 — consistent with Novartis's specialty drug pricing.

Total assets fluctuate dramatically year-over-year ($124.5M in 2019, $382.9M in 2024) because the foundation holds medication inventory rather than an investment endowment. Net investment income is zero across all years — revenue equals contributions from Novartis parent, and all funds flow immediately to program delivery.

There is no geographic allocation, no therapeutic area cap, and no limit on the number of patients served. Coverage is uniformly national (all US states and territories) across all medications on the current drug list. Program officers draw no compensation.

The five database-matched peers span two fundamentally different foundation models. Bayer US Patient Assistance Foundation is structurally analogous to NPAF; the other four are traditional health grant-making foundations with endowment portfolios and competitive grant cycles.

NPAF's $2.87B in annual giving dwarfs every peer by orders of magnitude — but this comparison is apples to oranges. Medication donations are valued at retail or wholesale cost, not cash equivalent, and the giving flows to individuals rather than nonprofits. Bayer US Patient Assistance Foundation is the most structurally comparable peer (NJ-based pharma PAP, similar asset base), but it does not publish granular giving totals. The three traditional health foundations — Unihealth, Valley Baptist, and Natrona — operate entirely different models with competitive reviews, geographic restrictions, and organizational grantees. NPAF's rolling, individual-patient enrollment is accessible to any qualifying US patient at any time, distinguishing it from all four peers in the database.

The most concrete recent development is NPAF's 2024-2025 income policy update, published by Novartis as a formal policy change document. Under the revised guidelines, patients on Medicaid, government insurance (Tricare, DoD, VA), or without insurance must report household incomes at or below $81,760 for a household of two. Thresholds scale per FPL guidelines for larger households and vary by specific medication — a level of specificity that marks a tightening from prior program language.

Financially, NPAF's FY2024 Form 990 (filed October 23, 2025) shows total revenue of $3.38B — a 19% increase over FY2023's $2.83B in contributions received. This suggests either more patients being served, a richer drug mix (higher per-unit cost), or both. Grants paid for FY2024 had not been independently reported at time of research.

Looking ahead to 2026, Novartis publicly committed to meeting US administration drug pricing priorities and pledged to make additional medicines available through direct-to-patient platforms in 2026. For NPAF, this is a meaningful signal: the covered drug list is likely to expand, potentially including newer high-cost oncology and rare disease agents.

Leadership composition has been stable across multiple 990 filings, with Tom Kendris holding the presidency and a board including CFO Katherine Vazquez and Treasurer John McKenna — all without compensation. The foundation's NJ address (Tax Dept, One Health Plaza, East Hanover) and phone number (862-778-1644) are unchanged. No leadership transitions or board overhauls were identified in web research.

NPAF's application process has several non-obvious features that determine approval speed and success rate — particularly for healthcare organizations enrolling multiple patients.

Verify medication eligibility before anything else. NPAF covers only Novartis medications on its current published list. A patient prescribed an unlisted drug — or a Novartis drug whose coverage was discontinued — will be automatically denied. Visit pap.novartis.com, select the specific medication, and confirm both that it is listed and that the patient meets that medication's specific income threshold. The general 2025 ceiling ($81,760 for household of two) is a floor, not a universal limit — individual drug pages may show stricter thresholds.

The prescriber section is structurally required, not optional. The NPAF Enrollment Application has two sections that must be submitted together: the patient section and the healthcare provider (prescriber) section. An incomplete prescriber section guarantees processing delays. Healthcare organizations should build prescriber co-signature into their standard prescription workflow — not as a follow-up step after the patient has already completed their section.

Tax returns are the only accepted income documentation by default. Submit the first two pages of the patient's most recent federal Form 1040. Patients who did not file — a common situation for very low-income individuals — should call 1-800-277-2254 (Mon–Fri, 9am–6pm EST) to confirm acceptable alternative income documentation before submitting, rather than discovering the gap after a denial.

Fax is operationally superior to mail. Fax to 1-855-817-2711 for faster queue entry and easier confirmation of receipt. Mail applications go to PO Box 2529, Columbus, OH 43216. Both routes produce decisions within approximately four weeks from receipt of a complete application.

Renewal is the highest-risk failure mode for long-term patients. Assistance is time-limited and expires. Patients who let their approval lapse face a medication access gap that can last up to four weeks while a renewal is processed. Track every enrolled patient's expiration date and initiate renewal at least 60 days before expiration with updated income documentation.

Screen for the alternate funding program disqualifier at intake. NPAF explicitly excludes patients enrolled in insurance arrangements that condition coverage on NPAF participation. This is a hard disqualifier — no appeal pathway exists if this condition is met.